14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IHE vs IHI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
IHE Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 3–0 Matrix Metrics)
IHE Overall Winner
6-Pillar Tally: IHE 0 – 0 IHI (6 Tie)
Matrix Metrics: IHE 3 – 0 IHI
As of Nov 16, 2026, iShares U.S. Pharmaceuticals ETF (IHE) is the stronger overall head-to-head candidate over iShares U.S. Medical Devices ETF (IHI) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). IHE carries a Unified Composite Score of 39.6/100 (SELL) at $109.89 (N/M Forward P/E, N/A operating margin), whereas IHI carries 32.0/100 (SELL) at $57.66 (N/M Forward P/E, N/A operating margin).
Defensive Composite Rating Caution: Although IHE compares more favorably head-to-head, both IHE (39.6/100 SELL) and IHI (32.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IHE vs IHI. Trailing 12-month operating profitability (IHE N/A vs IHI N/A) and valuation multiples (IHE N/M vs IHI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IHE vs IHI Key Questions & Quantitative Answers
As of Nov 16, 2026, iShares U.S. Pharmaceuticals ETF (IHE) is the stronger overall head-to-head candidate over iShares U.S. Medical Devices ETF (IHI) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). IHE carries a Unified Composite Score of 39.6/100 (SELL) at $109.89 (N/M Forward P/E, N/A operating margin), whereas IHI carries 32.0/100 (SELL) at $57.66 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although IHE compares more favorably head-to-head, both IHE (39.6/100 SELL) and IHI (32.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
IHE and IHI split Growth & Scale metrics: IHE posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with IHI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, IHE generates N/A in USD-normalized revenue versus N/A for IHI. In operating R&D and SG&A reinvestment, IHE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IHI.
IHE and IHI trade at balanced relative valuation multiples. IHE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IHI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IHE (N/A ROE) versus IHI (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, IHE carries 15.3% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.40β · 25% Vol realized risk). By comparison, IHI carries 17.6% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.41β · 34% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.